The 2019 Annual General Meeting will be held on 26 March 2019 in Helsinki. Registration closes on 20 March. Instructions and registration link can be found on these pages.
|3/4/2019||Orion Group Financial Statement documents 2018 and Corporate Governance Statement published|
|3/1/2019||Orion Corporation: Transfer of 47,279 own B shares on 1 March 2019|
|2/6/2019||The Board of Directors of Orion Corporation decided on an incentive plan for key persons|
|2/6/2019||Notice to the Annual General Meeting of Orion Corporation|
|3/8/2019||Darolutamide submitted for European marketing authorization|
|3/5/2019||Darolutamide submitted for marketing authorization in Japan|
|2/27/2019||The rolling submission to FDA for darolutamide in the U.S. completed|
|2/14/2019||Orion's and Bayer's darolutamide shows substantial efficacy and a favourable safety profile in the treatment of prostate cancer in the ARAMIS trial|
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
One key area of Orion's business is Critical Care. Our portfolio includes Simdax® for acute heart failure and Precedex® and Dexdor® for sedation. Read more about Orion's proprietary products and other human pharmaceuticals.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.